Qualitative Exploration of Key Symptoms of Stricturing Crohn's Disease: Toward the Development of a Clinical Assessment Score.
Condition(s) studied
Investigational drug(s) / intervention(s)
Semi-structured interview: One-hour semi-structured interview in person or by videoconference. Interviews will be audio-recorded, pseudonymized, transcribed, and analyzed, and participants can review their transcripts before final anonymization.
Study summary
The goal of this qualitative study is to identify and better understand the symptoms of stricturing Crohn's disease in order to inform the development of more appropriate clinical evaluation scores. This study focuses on adult patients diagnosed with stricturing Crohn's disease who are followed in hospital gastroenterology departments.
The main questions it aims to answer are:
* Which symptoms are perceived by patients as the most specific and significant features of stenosing Crohn's disease?
* Which symptoms are perceived by patients as early warning signs of a stenosing flare?
* How does stenosing Crohn's disease impact daily life, mental health, and quality of life, and what coping strategies do patients use to manage symptoms and limit their impact?
Participants will:
* Take part in a one-hour individual semi-structured interview, conducted in person (at the hospital, at home, or in another agreed location) or by videoconference
* Have the interview audio-recorded for transcription and qualitative analysis
* Be offered the opportunity to review and validate the transcript and summary of their interview before final anonymized analysis
Eligibility
Primary outcome measure(s)
- Frequency of patient-reported symptom categories associated with stenosing Crohn's disease, derived from thematic content analysis of single semi-structured interviews. — Up to 5 months
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| CHU Grenoble Alpes | La Tronche | France |
More University Hospital, Grenoble trials in France
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07441629 on ClinicalTrials.gov ↗ ← All trials in France